Immunohistochemical expression of PTEN (phosphatase and tension homolog) in endometrial carcinoma
Keywords:Endometrial carcinoma, PTEN, Immunohistochemistry
Background and objective: Different molecular alterations have been described in the pathogenesis of endometrial carcinoma, among themis mutation of the PTEN (phosphatase and tension homolog), a tumor suppressor gene. This study aimed to detect PTEN immunoexpression in endometrial carcinoma and to asses the association between PTEN immunoexpression with the clinicopathological parameters.
Methods: This cross-sectional retrospective study was carried out between January 2016-December 2021 in Erbil city. A total of 112 formalin fixed, paraffin embedded, archival tissue blocks of total abdominal hysterectomy samples were collected in Erbilcity. The clinicopathological characteristics of the tumors were revised, and the specimens were analyzed immunohistochemically using monoclonal PTEN antibody clone 6H2.1 (Dako.
Results: Seventy- seven cases (68.8%) were labeled as negative for PTEN immunoexpression. While 35 cases (31.2%) were labeled as positive for PTEN immunoexpression. PTEN immunoexpression was significantly associated with the tumor histological types (P = 0.001), while no significant association was found between PTEN immunoexpression and other clinicopathological parameters.
Conclusion: Loss of PTEN immunoexpression frequently seen in endometrioid type of endometrial carcinoma than other types of endometrial carcinoma and is significantly associated with the histological types of endometrial carcinoma.
Arend RC, Jones BA, Martinez A, Goodfellow P. Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol Oncol. 2018; 150(3):569–80. https://doi.org/10.1016/j.ygyno.2018.05.015.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209–49. https://doi.org/10.3322/caac.21660.
Buhtoiarova TN, Brenner CA, Singh M. Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. Am J Clin Pathol. 2016; Endometrial Carcinoma: 145(1):8–21. https://doi.org/10.1093/ajcp/aqv014.
Stavropoulos A, Varras M, Vasilakaki T, Varra VK, Tsavari A, Varra FN, et al. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett. 2019; 17(5):4575–89. https://doi.org/10.3892/ol.2019.10093.
Chen R, Zhang M, Liu W, Chen H, Cai T, Xiong H, et al. Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma. Cell Death Dis. 2018; 10(1):1–13. https://doi.org/10.1038/s41419-018-1207-4.
Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017; 145(1):200–7. https://doi.org/10.1016/j.ygyno.2016.12.015.
Ciuffreda L, Falcone I, Cesta Incani U, Del Curatolo A, Conciatori F, Matteoni S, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul. 2014; 56:66–80. https://doi.org/10.1016/j.jbior.2014.07.002.
Travaglino A, Raffone A, Saccone G, Mascolo M, Pignatiello S, Mollo A, et al. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS. 2019; 127(4):161–9. https://doi.org/10.1111/apm.12938.
Pasanen A, Loukovaara M, Bützow R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod Pathol. 2020; 33(7):1443–52. https://doi.org/10.1038/s41379-020-0501-8.
Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016; 3(1):14. https://doi.org/10.1186/s40661-016-0035-4.
Thukral S, Bhat S, Bashir N. Study of expression of PTEN and Cyclin D1 in endometrium at a tertiary care centre. Int J Adv Med. 2019; 6(2):495–501. http://doi.org/10.18203/2349-3933.ijam20191165.
Shanmugapriya DM, Sudha DM, Prakash DG. A study of PTEN expression in endometrial hyperplasia and endometrioid type of endometrial carcinoma. Trop J Pathol Microbiol. 2017; 3(1): 39–45. https://doi.org/10.17511/jopm.2017.i01.07.
Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar S. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol. 2009; 4(1):41. https://doi.org/10.1186/1746-1596-4-41.
Sithara S, Varghese S, Sankar S. Phosphotensin tumour suppressor gene (pten) expression patterns in endometrial hyperplasias and endometrioid carcinoma. J Evol Med Dent Sci. 2019; 8(7):403–6. https://doi.org/ 10.14260/jemds/2019/89.
Akiyama-Abe A, Minaguchi T, Nakamura Y, Michikami H, Shikama A, Nakao S, et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. Br J Cancer. 2013; 109(6):1703–10. https://doi.org/10.1038/bjc.2013.455.
Yang X, Ma K, Chen R, Zhang N, Meng Y, Wen J, et al. Immunocytochemical examination of PTEN and Ki-67 for endometrial carcinoma using thin-layer endometrial preparations. BIOCELL 2021; 45(4):923–32. https://doi.org/: 10.32604/biocell.2021.013625
Raffone A, Travaglino A, Saccone G, Campanino MR, Mollo A, De Placido G, et al. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019; 98(3):275–86. https://doi.org/10.1111/aogs.13513.
Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017; 3(4):279–93. https://doi.org/10.1002/cjp2.82.
Daniilidou K, Frangou-Plemenou M, Grammatikakis J, Grigoriou O, Vitoratos N, Kondi-Pafiti A. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. JBU. 2013; 18(1):108.
Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathological Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2012; 31(1):48–56. https://doi.org/10.1097/PGP.0b013e3182230d00.
Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012; 25(5):699–708. https://doi.org/10.1038/modpathol.2011.208.
Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer. 2010; 46(8):1365–73. https://doi.org/10.1016/j.ygyno.2018.05.015.
Gao Q, Ye F, Xia X, Xing H, Lu Y, Zhou J, et al. Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2009; 29(1):59–63. https://doi.org/10.1007/s11596-009-0112-6
Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011; 104(9):1505–10. https://doi.org/10.1038/bjc.2011.68
Malpica A, Euscher ED, Hecht JL, Ali-Fehmi R, Quick CM, Singh N, et al. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists. Int J Gynecol Pathol. 2019; 38(1):S9–24. https://doi.org 10.1097/PGP.0000000000000552
Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers. 2021; 13(11):2623. https://doi.org/10.3390/cancers13112623.
Chen CY, Chen J, He L, Stiles BL. PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol. 2018; 9:338. https://doi.org/10.3390/cancers13112623.
Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers 2019; 11(8):1076. https://doi.org/10.3390/cancers11081076.
Niwa K, Mori M, Miyazaki T, Tanaka T, Morishige KI. Conservative Medroxyprogesterone Acetate Therapy in Early Stage of Endometrial Carcinoma Associated with Phosphatase and Tensin Homolog Expression. Open J Pathol. 2017; 07(01):1–12. https://doi.org/10.4236/ojpathology.2017.71001 .
Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. Int J Gynecol Pathol. 2020; 39(1):26–35. https://doi.org/ 10.1097/PGP.0000000000000585.
Znaor A, Fouad H, Majnoni d’Intignano F, Hammerich A, Slama S, Pourghazian N, et al. Use of cancer data for cancer control in the Eastern Mediterranean Region: Results of a survey among population-based cancer registries. Int J Cancer. 2021; 148(3):593–600. https://doi.org/10.1002/ijc.33223.
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014; 15(7):e268–78. https://doi.org/ 10.1097/PGP.0000000000000491.
Allithy AN, Ammar IMM, Mohammed MH. Diagnostic and Prognostic Values of PTEN Expression in Functional and Pathological Endometrial Biopsies. Asian Pac J Cancer Biol. 2022; 7(1):21–7. https://doi.org/10.31557/APJCB.2022.7.1.21-27.
Saleh M, Virarkar M, Bhosale P, El Sherif S, Javadi S, Faria SC. Endometrial Cancer, the Current International Federation of Gynecology and Obstetrics Staging System, and the Role of Imaging. J Comput Assist Tomogr. 2020; 44(5):714–29. https://doi.org/10.1097/RCT.0000000000001025.
How to Cite
Copyright (c) 2023 Zena Adwal Ali, Payman Anwar Rashid Berzinji (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).